东亚药业(605177.SH)前三季度净亏损7240.96万元

Group 1 - The core point of the article is that Dongya Pharmaceutical (605177.SH) reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Group 2 - The total operating revenue for the first three quarters of 2025 was 596 million yuan, representing a year-on-year decrease of 38.08% [1] - The net profit attributable to shareholders of the parent company was -72.41 million yuan, compared to a net profit of 45.17 million yuan in the same period last year [1] - The basic earnings per share were -0.63 yuan [1]